SUNNYVALE, Calif., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Amarantus BioSciences Inc. (OTCBB:AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Recently, the biotech company released a video interview with its CEO, Gerald Commissiong that covers its development of MANF. Unlike Insmed Inc. (Nasdaq:INSM) or Alexion Pharmaceuticals Inc. (Nasdaq:ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide range of conditions. Recently, the company updated shareholders on its expanded corporate strategy and execution.
